Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #74 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Indoco Remedies Limited (this stock) | 2,415 | 23.1 | -10.6% | -9.8% | — | 46 | 72 | 85 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 468 | 78 | 65 | ₹ |
| March 31, 2026 | 476 | -25 | -24 | ₹ |
| Dec. 31, 2025 | 445 | -31 | -29 | ₹ |
| Sept. 30, 2025 | 485 | -14 | -9 | ₹ |
| June 30, 2025 | 438 | -37 | -36 | ₹ |
| March 31, 2025 | 390 | -46 | -41 | ₹ |
| Dec. 31, 2024 | 411 | -31 | -28 | ₹ |
| Sept. 30, 2024 | 433 | -5 | -10 | ₹ |
| June 30, 2024 | 431 | 7 | 2 | ₹ |
| March 31, 2024 | 450 | 33 | 22 | ₹ |
| Dec. 31, 2023 | 459 | 23 | 16 | ₹ |
| Sept. 30, 2023 | 482 | 46 | 35 | ₹ |
| June 30, 2023 | 426 | 34 | 24 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 1,845 | -107 | -99 |
| March 31, 2025 | 1,665 | -74 | -78 |
| March 31, 2024 | 1,817 | 136 | 97 |
| March 31, 2023 | 1,669 | 193 | 142 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 192 | -102 | -77 | 148 | 45 |
| March 31, 2025 | 95 | -339 | 241 | 356 | -261 |
| March 31, 2024 | 157 | -434 | 280 | 427 | -271 |
| March 31, 2023 | 179 | -208 | 23 | 207 | -28 |
| March 31, 2022 | 174 | -121 | -44 | 125 | 49 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 2,593 | 932 | 921 | 520 | 516 | 1,193 | 1,053 | 26 | 970 | 405 |
| March 31, 2025 | 2,430 | 1,018 | 1,004 | 451 | 543 | 1,001 | 808 | 12 | 849 | 419 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
